evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,678 questions · 4,859 findings · 283 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1,225 · 25.2%GRADE not reported 215 · 4.4%Very low 1,241 · 25.5%Low 1,210 · 24.9%Moderate 776 · 16%High 192 · 4%

Summary of findings table ‐ Starting long‐term oral antiplatelet therapy vs avoiding antithrombotic therapy

All major occlusive vascular events · survivors of stroke due to intracerebral haemorrhage

Summary of findings table ‐ Starting long‐term oral antiplatelet… showed no clear difference in all major occlusive vascular events compared with avoiding antithrombotic therapy (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Starting long‐term oral antiplatelet therapy vs avoiding antithrombotic therapy

Intracerebral haemorrhage (ICH) · survivors of stroke due to intracerebral haemorrhage

Summary of findings table ‐ Starting long‐term oral antiplatelet… showed no clear difference in intracerebral haemorrhage (ICH) compared with avoiding antithrombotic therapy (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Starting long‐term oral antiplatelet therapy vs avoiding antithrombotic therapy

Functional outcomes · survivors of stroke due to intracerebral haemorrhage

Summary of findings table ‐ Starting long‐term oral antiplatelet… showed no clear difference in fnctional status (mRS 0‐2) compared with avoiding antithrombotic therapy (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Oral small molecule inhibitors (ruxolitinib) vs oral small molecule inhibitors (tofacitinib)

Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata

It is very uncertain whether summary of findings table ‐ Oral small molecule inhibitors… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with oral small molecule inhibitors (tofacitinib) (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Promotion/universal prevention interventions vs control group

Diagnosis of mental disorders at study endpoint · preventing mental disorders
2 findings from 1 review

Summary of findings table ‐ Promotion/universal prevention interventions vs control group

QoL · preventing mental disorders
2 findings from 1 review

Summary of findings table ‐ Promotion/universal prevention interventions vs control group

Adverse events at study endpoint · preventing mental disorders
2 findings from 1 review

Summary of findings table ‐ Promotion/universal prevention interventions vs control group

Psychological functioning and impairment at study endpoint (higher score = higher disability) · preventing mental disorders
2 findings from 1 review

Summary of findings table ‐ Promotion/universal prevention interventions vs control group

Depressive symptoms · preventing mental disorders
2 findings from 1 review

Summary of findings table ‐ Promotion/universal prevention interventions vs control group

Anxiety · preventing mental disorders
2 findings from 1 review

Summary of findings table ‐ Promotion/universal prevention interventions vs control group

Distress/PTSD symptoms at study endpoint (higher score = higher severity) · preventing mental disorders
2 findings from 1 review

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy vs chemotherapy alone

Progression‐free survival · newly‐diagnosed EOC

It is very uncertain whether summary of findings table ‐ Newly‐diagnosed EOC: PARPi with… changes progression‐free survival (PFS) compared with chemotherapy alone (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy vs chemotherapy alone

Adverse events (grade ≥ 3) · newly‐diagnosed EOC

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with… leads to higher any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with chemotherapy alone (high certainty).

1 finding from 1 review

Summary of findings for combination antimicrobial susceptibility testing vs conventional treatment (separate testing)

Lung function(FEV1 or FVC L/min or % predicted) · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa

The review found no eligible studies for this question.

1 finding from 1 review